Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04949256 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
A Phase 3 study of Metastatic Esophageal Squamous Cell Carcinoma, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 3
- Development phase
- 864
- Enrollment target
- 20
- Study locations
NCT04949256 is a Phase 3 study of Metastatic Esophageal Squamous Cell Carcinoma that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 864 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT04949256, a Phase 3 study of Metastatic Esophageal Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 864 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus chemotherapy as first-line intervention in participants with metastatic esophageal carcinoma. The primary hypotheses are that pembrolizumab plus lenvatinib plus chemotherapy is superior to pembrolizumab plus chemotherapy with respect to overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR). As of Amendment 09, Study MK-7902-014 will begin close out activities. Any participant who discontinues study intervention for any reason will be discontinued from the study without further follow-up. Second Course and treatment beyond disease progression will no longer be offered. No safety concerns contributed to the termination of this study.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Cisplatin
- DRUG Oxaliplatin
- DRUG Lenvatinib
- DRUG 5-FU
Study Locations (20)
New York
- Hematology-Oncology Associates of CNY ( Site 0173) - East Syracuse
- Memorial Sloan Kettering Cancer Center ( Site 0132) - New York
- Weill Cornell Medical College ( Site 0133) - New York
Buenos Aires
- Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 0203) - Berazategui
- IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 0202) - CABA
- Instituto de Investigaciones Clinicas Mar del Plata ( Site 0205) - Mar del Plata
Kentucky
- James Graham Brown Cancer Center ( Site 0117) - Louisville
- Norton Cancer Institute ( Site 0116) - Louisville
Pennsylvania
- St. Luke's University Health Network ( Site 0185) - Bethlehem
- AHN Allegheny General Hospital ( Site 0164) - Pittsburgh
Santa Fe Province
- Fundacion Estudios Clinicos-Oncology ( Site 0215) - Rosario
- Sanatorio Parque ( Site 0206) - Rosario
California
- City of Hope ( Site 0102) - Duarte
District of Columbia
- MedStar Washington Hospital Center ( Site 0186) - Washington D.C.
Maryland
- Johns Hopkins Bayview Medical Center ( Site 0152) - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 864 participants |
| Start Date | 2021-07-28 |
| Est. Completion | 2026-06-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04949256
The ClinicalTrials.gov registry entry for NCT04949256 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 864 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Esophageal Squamous Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT04949256 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New York, Buenos Aires, Kentucky.
Frequently Asked Questions
What is clinical trial NCT04949256 about?
NCT04949256 is a clinical study titled "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)". The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus chemotherapy as first-line intervention in participants with metastatic esophageal carcinoma. The primary hypotheses are that pembrolizumab plus lenvati...
What is the current status of trial NCT04949256?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 864 participants. The study started on 2021-07-28. Estimated completion is 2026-06-12.
What conditions does trial NCT04949256 study?
This clinical trial studies the following conditions: Metastatic Esophageal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT04949256?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Cisplatin (DRUG), Oxaliplatin (DRUG), Lenvatinib (DRUG), 5-FU (DRUG).
Who is sponsoring clinical trial NCT04949256?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04949256 being conducted?
This trial has 20 study locations across California, District of Columbia, Kentucky, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Esophageal Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.